Protagenic Therapeutics Inc. (MBP)
XMUN 
Summary
MBP Chart
Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split
Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, today announced that the Company's Board of Directors has approved a 1-for-14 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") to be effective 12:01 a.m., Eastern Time, on May 5, 2025.
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date, and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants was $0.64 ($0.89 in the case of insiders).
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock (or pre-funded warrants in lieu of shares of common stock), series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date (as defined in the Purchase Agreement), and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of Common Stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants will be $0.64 ($0.89 in the case of insiders).
Protagenic Therapeutics Inc. Dividends
| PTIX 5 Dec 2005 Paid | Other | $100,000 Per Share |
Protagenic Therapeutics Inc. Earnings
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 May 2024 Date | | - Cons. EPS | - EPS |
| PTIX 5 Dec 2005 Paid | Other | $100,000 Per Share |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 May 2024 Date | | - Cons. EPS | - EPS |
Protagenic Therapeutics Inc. (MBP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Protagenic Therapeutics Inc. ever had a stock split?
Protagenic Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Garo H. Armen Ph.D. CEO | XMUN Exchange | US74365N2027 ISIN |
| US Country | 1 Employees | 27 Jul 2016 Last Dividend | 5 May 2025 Last Split | 5 Jan 2016 IPO Date |
Overview
Protagenic Therapeutics, Inc. is a biopharmaceutical company with a dedicated focus on the discovery and development of novel therapeutics aimed at treating stress-related neuropsychiatric and mood disorders. With a headquarters based in New York, New York, the company leverages cutting-edge science to create solutions that can significantly improve the mental health outcomes for individuals suffering from these conditions. Through its innovative approach, Protagenic Therapeutics, Inc. seeks to address the complex challenges associated with stress and mood disorders, unlocking new possibilities for treatment and care in the mental health landscape.
Products and Services
- PT00114
PT00114 stands as the lead compound in the developmental pipeline of Protagenic Therapeutics, Inc. This synthetic form of teneurin carboxy-terminal associated peptide represents a groundbreaking advancement in the treatment of neuropsychiatric and mood disorders. As an endogenous brain signaling peptide, it has the unique capacity to dampen overly active stress responses, providing a novel mechanism of action compared to traditional therapies. PT00114 is the cornerstone of Protagenic Therapeutics, Inc.'s endeavors, embodying the company's commitment to introducing innovative and effective treatments in the realm of mental health.
Contact Information
